Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596723 · ClinicalTrials.gov registry record · Phase 3
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
A Phase 3 study, sponsored by Kala Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT03596723 is a Phase 3 study that was terminated before completion, run by Kala Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT03596723, a Phase 3 study, was terminated before completion, sponsored by Kala Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.
Interventions
- DRUG Prednisolone acetate
- DRUG KPI-121 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2018-10-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596723
The ClinicalTrials.gov registry entry for NCT03596723 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kala Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisolone acetate is the first listed.
NCT03596723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596723 about?
NCT03596723 is a clinical study titled "KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children". This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.
What is the current status of trial NCT03596723?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2018-07-03. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT03596723?
The interventions under investigation include: Prednisolone acetate (DRUG), KPI-121 1% (DRUG).
Who is sponsoring clinical trial NCT03596723?
This trial is sponsored by Kala Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.